Key facts: Cencora FY26 growth; OneOncology margins; Leerink target up
Cencora reported fiscal 2026 revenue of $337.4B, up 5%, and adjusted EPS of $17.97, up 12.3%. The company forecast fiscal 2027 EPS of $19.40–$19.75 and raised its dividend by 10%. OneOncology acquisition improved margins, partly offset by lower-margin GLP-1 sales. Leerink Partners increased its price target to $405 from $388.
How this was made
The 30-second read
Why it matters
The earnings beat and dividend hike provide a fresh catalyst for price appreciation, especially after the analyst target raise.
Market read
First report of FY26 earnings and FY27 guidance for a $300B+ revenue pharma distributor, likely to move the stock and sector.
What to watch
Potential margin pressure from higher GLP‑1 sales and integration costs of OneOncology.
Background
Cencora (formerly AmerisourceBergen) is a leading drug distributor; the article summarizes its FY26 results and FY27 outlook.
Ticker impact
Cencora reported FY26 revenue of $337.4B, EPS $17.97 and raised FY27 EPS guidance to $19.40‑$19.75 plus a 10% dividend increase.
upward pressure as the market prices in higher earnings and dividend increase
Large‑cap pharma with material revenue, EPS beat and dividend hike; analysts upgraded target, indicating fresh positive catalyst.
Market effects
Strengthens outlook for the pharmaceutical distribution sector, may lift peers.
Positive for U.S. healthcare stocks and dividend‑focused investors.
Reinforces confidence in large‑cap pharma earnings trends globally.
Counterpoint
If guidance falls short of analyst consensus, the stock could face short‑term profit‑taking.
Key entities
- companyCencora, Inc.
U.S. pharmaceutical distributor, ticker COR.
- analystLeerink Partners
Raised price target for Cencora to $405.
